江蘇吳中(600200.SH):鹽酸曲美他嗪片(20mg)擬中標第三批全國藥品集採
格隆匯 8 月 20日丨江蘇吳中(600200.SH)公佈,2020年8月20日,公司所屬江蘇吳中醫藥集團有限公司蘇州製藥廠(“蘇州製藥廠”)參加了聯合採購辦公室組織的第三批全國藥品集中採購的投標工作。蘇州製藥廠已通過國家藥品監督管理局仿製藥質量和療效一致性評價的產品鹽酸曲美他嗪片(20mg)擬中標此次集中採購。
根據聯合採購辦公室及有關報道信息,除蘇州製藥廠外,此次鹽酸曲美他嗪片擬中標企業還有瑞陽製藥有限公司、遠大醫藥(中國)有限公司、北京福元醫藥股份有限公司3家公司。根據有關招標規則,此次擬中標的標期為三年。
蘇州製藥廠此次擬中標的產品鹽酸曲美他嗪片(20mg),2019年度銷售收入約為2872.08萬元,約佔公司2019年度營業收入的1.36%。
此次集中採購是國家組織的第三批藥品集中帶量採購,在執行上要求全國醫療機構優先使用集中採購中選品種,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將有利於擴大相關產品的銷售,提高市場佔有率,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.